A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Sponsor:
- SWOG
- Sponsor Study ID:
- S1900G
- CTO #:
- 103915
- NCT Number:
- NCT05642572
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- The primary objective is to compare investigator-assessed progression-free survival (IAPFS) between participants with EGFR mutated, MET amplified NSCLC randomized to INC280 (capmatinib) and osimertinib with or without ramucirumab
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Affiliate Principal Investigator, Lupak, Oleksandra, at oll203@musc.edu .
- Principal Investigator, Rangel, Christopher, at rangelc@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
-
Ralph H. Johnson VAMC
- Study Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov .
Trial opened at the following institutions:
Medical University of South Carolina, Ralph H. Johnson VAMC